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Traversing the valley of 
glycemic control despair
From Misplaced Hope to the Valley of Despair, … and Back To 
Informed Optimism?
J. Geoffrey Chase, Jennifer L. Dickson, Balazs Benyo
Glycemic Control (GC) today in one (1) word 
Contentious
• Or via Google Translate:
Vitás
• Today’s Goals:
• Is GC valuable?
• What are the needs? … or … Why hasn’t it succeeded?
• How to provide safe, effective GC to nearly all patients?
• Talk available at: http://tinyurl.com/ycwwjkvl
• All references (N=32) available at: http://tinyurl.com/yanndo82
Overview: The Valley of Despair (Kelley and Connor 1979)
Van den Berghe, NEJM 2001
Van den Berghe, NEJM 2006
Krinsley, May Clin Proc 2004
Chase, Critical Care 2008
Preiser, Int Care Med 2008
Brunkhorst, Int Care Med 2008
Many other “no results”
NICE-SUGAR, Finfer, NEJM 2009
Higher BG Targets
Ichai, Critical Care 2010
Moghissi, Diabetes Care 2009
Better Control
Evans, Annals ICU 2010
Tanenberg, Endo Prac 2017
Replicable Control as Std of Care
Stewart, Annals ICU 2010
Proof GC is the cause not the effect
Uyttendaele, Critical Care 2017
Positive Associations: Mortality, Morbidity, Cost
Positive Associations: Mortality, Morbidity, Cost



















































The Negative Associations: Hypos + Variability






The Real Question: Associations and Causality
The New Pessimism
• Does GC cause hypos and variability and death, because those who die are more likely to 
be more resistant, variable and hard to control?
Or …
The Original Optimism
• Does good GC cause better outcomes as we expect?
Are Patients Who Die Harder to Control?
• If yes, then GC is a bad idea as it creates more hypos and variability, particularly among 
those more likely to die 
• The associations are a function of morbidity and eventual mortality – GC offers no benefit and 
possible harm
• If no, then glycemic level and variability are strictly a function of the GC given (or not), and 
thus outcomes (and association with mortality) follow from that GC
• The associations are caused by poor GC and safe, effective GC reduces morbidity and mortality
Are Patients Who Die Harder to Control?
• A clinically very well validated (over 50 journal articles) measure of metabolic level (SI) 
and its hour-to-hour variability (%DSI) in 6-hour blocks over 1st 72 hours
• Compare those who lived with those who died over first 72 hours
• SI  is insulin resistance the same?
• %DSI is variability (the hard part of control) the same?
• Tested for statistical difference using bootstrapping (most robust means)
• Are they different?
• Not different (p > 0.05) does NOT mean THE SAME
• Tested for statistical equivalence (within one measurement error std deviation)
• Are they the same (to within measurement error)?
• Equivalent SI and %DSI in any 6-hour block  not harder to control
No! Dysglycemia  Mortality (not vice versa)
• SI is rarely different
• SI is never equivalent
• Those who die have higher SI than those 
who live !!
• Those who die are just a little easier to 
control in level (~0.5 U/hour less insulin for 
some, but p > 0.05)
No! Dysglycemia  Mortality (not vice versa)
• %DSI is never different
• %DSI is always equivalent
• Variability is equivalent between survivors 
and non-survivors
• No difference in ability to control, and 
thus should be no difference in hypos, 
and variability metrics
Therefore … 
• Glycemic control determines outcome (period, end of debate).
• But, then, why did the other trials all fail? 
• For whom is GC beneficial? All patients? Some patients
All Patients Must Receive Safe, Effective GC
• SPRINT achieved >98% of 
patients with cTIB > 50% 
within 2.5 days
• ~15% of patients have poor 
organ failure and poor GC 
(bottom right) in 
retrospective cohort
• If given good control, where 
do they go?
• No specific patient groups
• Thus, all must receive 
safe, effective control
Multi-centre trials had highly 
variable (poorer) control across 
ICUs
Yes
(+ very few others)
No
(and MANY others)
Safe, Effective GC For All?  (Studies > 100 patients, Standard of Care, …)
The ONLY study to reduce BOTH
mortality and hypoglycemia
The ONLY studies for >100 
patients and full LoS and/or are 
standard of care
No more than 70-75% (or less) of 
patients were in the targeted GC 
band… Covers the likely 15-20% 
who may benefit and the 
mortality differences in studies 
below
Needs (for all patients and ICUs) For Success
Safety
Minimal to Zero Hypoglycemia
Performance / Efficacy
High Time in Band
Replicability
Same in Every ICU




that is not ICU 
dependent
Personalisation is the key to 
Safety and Performance
It also requires 
compliance to 
protocol – good 
interface
Personalised
• STAR doses on risk and level using a patient-specific insulin sensitivity SI
• Risk is a function of future potential patient variability (%DSI)
• %DSI has been shown to be consistent across ICUs & cohorts (Dickson, IEEE Trans 2017)
• A measure of “How wrong can I be(come)?”
SI can change significantly over 1-3 hours  The root of (all?) GC problems!
Personalised
• STAR doses on risk and level using a patient-specific insulin sensitivity SI and %DSI 
Every patient is treated based on their patient-specific (at that time) SI level and their 
forecast risk of variation in SI  And thus every patient gets equal (good) control
Personalised
• STAR has 1% hypoglycemia by patient and 84% time in 4.4-8.0 mmol/band
• All patients with 24+ hours LoS have over 50% time in band
Control is world class, nutrition is ~ Best in World from survey of 158 ICUs (Cahill, 2010; Heyland 2011) 
85% ACCP goal = optimal amount for mortality, 
based on 158 ICU survey in 21 countries
Personalised  Replicable
• STAR had identical results in Christchurch and 
Gyula
• Patients in Gyula were much more ill (APACHE II 
28 vs 16)
• STAR had same approach but insulin and nutrition 
was administered very differently (infusions vs 
bolus; different nutrition composition, …)
The ability to deliver the same (good) glycemic 
control despite large differences in patient 
severity and clinical practice is the key to gaining 
benefits of GC
Personalised control enables this outcome!
A very short summary
• Humans are horribly variable  Personalised care is the answer
A brief pause for  reflection
Conclusions
• Glycemic control can (and does) affect outcomes
• Not controlling BG < 7.0 – 8.0 mmol/L affects morbidity, mortality, and cost
• Ignoring the problem is no longer an option
• Personalisation is the key to safe, effective GC for all – One Method Fits All
• And an end to “One size fits all” protocols
• Our goals should be safety, performance, and replicability – we should demonstrate these 
well before we implement or engage in a trial, as very few have been able to 
demonstrate all three criteria.
Talk available at: http://tinyurl.com/ycwwjkvl
All references (30) available at: http://tinyurl.com/yanndo82
Conclusions
Questions (and the path forward)
